What CagriSema is
CagriSema is a once-weekly injection from Novo Nordisk that combines two drugs:
| Component | What it is | Role |
|---|---|---|
| Semaglutide 2.4 mg | GLP-1 receptor agonist, the active ingredient in Wegovy and Ozempic | Reduces appetite and slows stomach emptying |
| Cagrilintide 2.4 mg | Long-acting analogue of amylin, a hormone released with insulin after meals | Adds a separate satiety signal |
The idea is that acting on two appetite pathways at once produces more weight loss than either drug alone. Novo Nordisk is also developing cagrilintide on its own, in a separate program called RENEW, which is not covered by this profile.
Clinical evidence
REDEFINE 1: obesity without diabetes
REDEFINE 1 randomized 3,417 adults with overweight or obesity to CagriSema, semaglutide alone, cagrilintide alone, or placebo. Published in the New England Journal of Medicine in 2025:
- Body weight changed by −20.4% with CagriSema and −3.0% with placebo at 68 weeks, a difference of −17.3 percentage points.
- More participants on CagriSema reached weight-loss thresholds of 5%, 20%, 25%, and 30%.
- Gastrointestinal adverse events affected 79.6% of the CagriSema group and 39.9% of the placebo group. They were mainly transient and mild to moderate.
REDEFINE 2: obesity with type 2 diabetes
In 1,206 people with overweight or obesity and type 2 diabetes, weight fell 13.7% with CagriSema and 3.4% with placebo at 68 weeks. Of those on CagriSema, 73.5% reached an HbA1c of 6.5% or lower, compared with 15.9% on placebo. Gastrointestinal events occurred in 72.5% versus 34.4%.
REDEFINE 4: head-to-head against tirzepatide
In February 2026, Novo Nordisk reported that REDEFINE 4, an open-label, 84-week head-to-head trial, did not meet its primary endpoint of showing that CagriSema was non-inferior to tirzepatide 15 mg for weight loss (company-reported):
| Analysis | CagriSema 2.4/2.4 mg | Tirzepatide 15 mg |
|---|---|---|
| If all participants adhered to treatment | −23.0% | −25.5% |
| Regardless of adherence (treatment-regimen estimand) | −20.2% | −23.6% |
Other results
In its August 2026 report, Novo Nordisk said REDEFINE 9, testing lower doses, achieved superior weight loss versus placebo. It also said REIMAGINE 4, in type 2 diabetes, showed CagriSema was non-inferior to tirzepatide for weight reduction but not for HbA1c reduction (company-reported).
Scientific perspective
CagriSema clearly produces large weight loss compared with placebo. REDEFINE 1 also included semaglutide-alone and cagrilintide-alone groups for comparison. The commercial and clinical question is comparative. Tirzepatide is already approved and widely used, and in REDEFINE 4 CagriSema could not demonstrate that it was at least as effective. The two estimands in the table above illustrate why trial reports often show two numbers: one asks what the drug can do when taken as directed, the other what happens in practice, including people who stop or switch. See What Is Statistical Significance in Clinical Trials?
Development perspective
- Regulatory status: not FDA-approved. openFDA lists no application record. Novo Nordisk reports a U.S. submission in December 2025 and anticipated an FDA decision by late 2026 (company-reported).
- Historical benchmark: about 90.6% of applications that reach the FDA have eventually been approved, often after resubmission. That figure is industry-wide and is not a prediction for CagriSema.
- Cardiovascular outcomes: REDEFINE 3, with 7,101 participants, has an estimated primary completion in September 2027 (registry).
- Pipeline changes: two CagriSema trials of new formulations are listed as withdrawn "due to strategic reasons" (registry), and a higher-dose trial is expected to read out in the first half of 2028 (company-reported).
Competitive context
CagriSema would compete with tirzepatide (Zepbound), semaglutide (Wegovy), and Lilly's oral orforglipron (Foundayo), with retatrutide expected to be filed in 2027. Its differentiator is the amylin mechanism. Its challenge, after REDEFINE 4, is showing a clinical reason to choose it over the established leader.
Development timeline
- Nov 1, 2022REDEFINE 1 Phase 3 trial begins. Registry
- Mar 1, 2023REDEFINE 3 cardiovascular outcomes trial begins. Registry
- Jun 22, 2025REDEFINE 1 and REDEFINE 2 published: weight loss of 20.4% and 13.7% at 68 weeks, versus 3.0% and 3.4% with placebo. Peer-reviewed
- Dec 2025CagriSema submitted to the U.S. FDA for weight management. Company-reported
- Feb 23, 2026Novo Nordisk reports REDEFINE 4 did not meet its primary endpoint of non-inferiority to tirzepatide on weight loss. Company-reported
- Aug 4, 2026Novo Nordisk reports REDEFINE 9 (lower doses) achieved superior weight loss versus placebo, and REIMAGINE 4 showed non-inferiority to tirzepatide on weight but not HbA1c. Company-reported
What could change the outlook
- The FDA decision on the weight-management application, which Novo Nordisk expected by late 2026.
- How the label and market positioning reflect the REDEFINE 4 result against tirzepatide.
- The REDEFINE 3 cardiovascular outcomes result (registry estimates primary completion in September 2027).
- The higher-dose CagriSema trial, which Novo Nordisk expects to read out in the first half of 2028 (company-reported).
- Gastrointestinal tolerability, reported in about 80% of REDEFINE 1 participants on CagriSema.
Latest company disclosures
Company press releases (SEC filings and PR Newswire) that mention CagriSema. Company-reported, not independently verified.
- Quarterly reportCompany-reportedNov 4, 2026
Financial report for the period 1 January 2026 to 30 September 2026
Pipeline progress • Within obesity, CagriSema (1.0/1.0 mg) delivered encouraging weight loss of 21% at week 68 in the REDEFINE 9 trial. • Also in obesity, the AMAZE 9 phase 3 trial with oral zenagamtide has been initiated in September. • Within diabetes, CagriSema (1.0/1.0 mg) achieved superior weight loss of 12.4%...
- Trial resultsCompany-reportedOct 29, 2026
Novo to present new CagriSema and Wegovy® data at ObesityWeek® 2026, including data on treatment experience with Wegovy® pill in the real world
Novo Nordisk today announced that new data from its obesity portfolio will be presented across 26 abstracts at ObesityWeek ® 2026, taking place November 14–17 in Washington, D.C., US.
- Trial resultsCompany-reportedOct 20, 2026
Novo's CagriSema was associated with 25% weight loss on average for women in a post hoc analysis of REDEFINE 1 presented at The Menopause Society Annual Meeting
Today, Novo announced results from two post hoc analyses of the REDEFINE 1 trial presented at The Menopause Society 2026 Annual Meeting in San Diego.